skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
B-Raf/VEGFR-2 Inhibitor RAF265 (Code C61311)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: B-Raf/VEGFR-2 Inhibitor RAF265

Definition: An orally bioavailable small molecule with potential antineoplastic activity. CHIR-265 binds and inhibits Raf kinases, which may result in a reduction of tumor cell growth and proliferation, and tumor cell death. In addition, this agent inhibits vascular endothelial growth factor receptor type 2 (VEGFR-2), thereby disrupting tumor angiogenesis. Raf kinases are critical enzymes in the Ras/Raf/MEK/ERK signaling pathway and are frequently upregulated in neoplasms.

NCI-GLOSS Definition: A substance being studied in the treatment of melanoma. CHIR-265 may block the growth of tumors and the growth of blood vessels from surrounding tissue to the tumor. It is a type of Raf kinase inhibitor and angiogenesis inhibitor.

Display Name: B-Raf/VEGFR-2 Inhibitor RAF265

Label: B-Raf/VEGFR-2 Inhibitor RAF265

NCI Thesaurus Code: C61311 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1831810  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
B-Raf/VEGFR-2 Inhibitor RAF265

External Source Codes: 
PDQ Closed Trial Search ID 484456
PDQ Open Trial Search ID 484456 (check for NCI PDQ open clinical trial info)
UMLS CUI C1831810

Other Properties:
     Name Value (qualifiers indented underneath)
code C61311
Contributing_Source CTRP
Legacy_Concept_Name CHIR-265
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom